Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesCD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection
BMC Cancer, 09/15/09
Yeh CT et al. – When HBV infection accounts for the major attributive risk of HCC, CD133 expression in HCC was negatively associated with the presence of HBsAg, implicating a non-viral origin of CD133-positive HCC. Additionally, CD133 expression predicted poor disease-free survival independently of p53 expression, arguing for two distinguishable hepatocarcinogenesis pathways.
Methods- 154 HCC patients receiving total removal of HCCs were included
- 104 (67.5%) were positive for HBV infection
- Cancerous and adjacent non-cancerous liver tissues were subjected for Western blot and immunohistochemistry analysis for CD133 expression
- Data were correlated with clinical parameters, patient survivals, and p53 expression
- Of 154 patients, 24 (15.6%) had CD133 expression in HCC
- Univariate and multivariate logistic regression analysis revealed CD133 expression was negatively correlated with presence of HBsAg
- p53 expression positively associated with the presence of HBsAg in univariate analysis
- Survival analysis indicated that both CD133 and p53 expression in HCC predicted poor disease-free survival whereas only CD133 expression predicted poor overall survival
- Cox proportional hazard model showed that p53 and CD133 expression were two independent predictors for disease-free survival
- Hazard ratios were 1.697 (95% CI 1.318 - 2.185) and 2.559 (95% CI 1.519 - 4.313), respectively
Today in Hepatobiliary/Pancreas...keeping you current
Receive free subspecialty "5-minute updates" via email
Macronutrients, fatty acids, cholesterol and pancreatic cancer
European Journal of Cancer, 10/27/09
Surgical management of hepatocellular carcinoma: Is the jury still out
Surgical Oncology, 11/05/09
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
British Journal of Cancer, 11/13/09
Sponsor
Article Search
Sponsor
Sponsor